• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CBAY

    CymaBay Therapeutics Inc.

    Subscribe to $CBAY
    $CBAY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

    IPO Year:

    Exchange: NASDAQ

    Website: cymabay.com

    Peers

    $CDTX
    $HALO
    $ONTX
    $TPTX
    $VKTX

    Recent Analyst Ratings for CymaBay Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    2/13/2024Outperform → Mkt Perform
    Raymond James
    8/14/2023$18.00Buy
    UBS
    8/11/2023$20.00Buy
    Guggenheim
    4/5/2023Outperform
    William Blair
    3/9/2023$15.00Buy
    BTIG Research
    4/11/2022$9.00Overweight
    Cantor Fitzgerald
    11/11/2021$12.00 → $14.00Strong Buy
    Raymond James
    8/3/2021$13.00 → $12.00Buy
    HC Wainwright & Co.
    See more ratings

    CymaBay Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Loewy Caroline M

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:09:21 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mcwherter Charles returned 46,938 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:06:11 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lefebvre Eric

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:05:48 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Dorling Janet

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:03:33 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shantharam Harish returned 20,125 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:03:16 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dickinson Klara returned 21,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 5:02:09 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quinlan Paul T returned 70,262 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 4:59:26 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wills Robert James returned 30,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 4:55:35 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shah Sujal returned 406,670 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 4:55:22 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Wiggans Thomas G

      4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)

      3/22/24 4:54:55 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CymaBay Therapeutics Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by CymaBay Therapeutics Inc.

      15-12G - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      4/1/24 6:04:16 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CymaBay Therapeutics Inc.

      EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/29/24 12:15:07 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CymaBay Therapeutics Inc.

      EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/29/24 12:15:28 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CymaBay Therapeutics Inc.

      EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/29/24 12:15:04 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CymaBay Therapeutics Inc.

      EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/29/24 12:15:12 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CymaBay Therapeutics Inc.

      EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/29/24 12:15:14 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by CymaBay Therapeutics Inc.

      S-8 POS - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/22/24 4:58:49 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by CymaBay Therapeutics Inc.

      S-8 POS - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/22/24 4:56:55 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by CymaBay Therapeutics Inc.

      S-8 POS - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/22/24 4:55:49 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by CymaBay Therapeutics Inc.

      S-8 POS - CymaBay Therapeutics, Inc. (0001042074) (Filer)

      3/22/24 4:54:49 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CymaBay Therapeutics Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for LIVDELZI issued to CYMABAY THERAPEUTICS INC

      Submission status for CYMABAY THERAPEUTICS INC's drug LIVDELZI (ORIG-1) with active ingredient SELADELPAR has changed to 'Approval' on 08/14/2024. Application Category: NDA, Application Number: 217899, Application Classification: Type 1 - New Molecular Entity

      8/14/24 12:53:53 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CymaBay Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CymaBay Therapeutics Inc. (Amendment)

      SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/14/24 4:46:08 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CymaBay Therapeutics Inc. (Amendment)

      SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/14/24 4:05:38 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CymaBay Therapeutics Inc. (Amendment)

      SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/14/24 9:09:24 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CymaBay Therapeutics Inc.

      SC 13G - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/13/24 5:02:41 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CymaBay Therapeutics Inc. (Amendment)

      SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/13/24 4:27:53 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CymaBay Therapeutics Inc.

      SC 13G - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      9/22/23 4:30:14 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CymaBay Therapeutics Inc.

      SC 13G - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      9/11/23 4:45:21 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CymaBay Therapeutics Inc.

      SC 13G - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      3/10/23 2:04:28 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CymaBay Therapeutics Inc. (Amendment)

      SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/14/23 4:06:08 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CymaBay Therapeutics Inc. (Amendment)

      SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)

      2/14/23 2:23:26 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CymaBay Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CymaBay Therapeutics downgraded by Raymond James

      Raymond James downgraded CymaBay Therapeutics from Outperform to Mkt Perform

      2/13/24 6:29:47 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on CymaBay Therapeutics with a new price target

      UBS initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $18.00

      8/14/23 7:12:38 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on CymaBay Therapeutics with a new price target

      Guggenheim initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $20.00

      8/11/23 7:12:36 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on CymaBay Therapeutics

      William Blair initiated coverage of CymaBay Therapeutics with a rating of Outperform

      4/5/23 8:55:52 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on CymaBay Therapeutics with a new price target

      BTIG Research initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $15.00

      3/9/23 7:09:11 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on CymaBay Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of CymaBay Therapeutics with a rating of Overweight and set a new price target of $9.00

      4/11/22 8:48:42 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James reiterated coverage on CymaBay Therapeutics with a new price target

      Raymond James reiterated coverage of CymaBay Therapeutics with a rating of Strong Buy and set a new price target of $14.00 from $12.00 previously

      11/11/21 9:22:27 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on CymaBay Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $12.00 from $13.00 previously

      8/3/21 6:24:20 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JonesTrading initiated coverage on CymaBay Therapeutics with a new price target

      JonesTrading initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $8.00

      6/14/21 8:59:23 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on CymaBay Therapeutics with a new price target

      Piper Sandler resumed coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $12.00

      3/9/21 12:30:32 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CymaBay Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gilead Sciences Announces Completion of Acquisition of CymaBay

      Acquisition Reinforces Gilead's Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (NASDAQ:GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (NASDAQ:CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead's existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients. "The acquisition of CymaBay brings us a potential best in disease therapy that

      3/22/24 9:18:00 AM ET
      $CBAY
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

      NEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the Marketing Authorization Application (MAA) for seladelpar, for the treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid), has been validated and will now be reviewed by the European Medicines Agency (EMA). Seladelpar is an investigational, potent, selective peroxisome proliferator-activated receptor delta (PPARδ)

      3/4/24 8:00:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

      Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing thera

      2/28/24 4:45:25 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis

      -  Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo -  NEWARK, Calif., Feb. 21, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that The New England Journal of Medicine (NEJM) has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, an investigational agent, and the only potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist or delpar, being studied in adults with primary biliary cholangitis (PBC). Re

      2/21/24 5:43:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees on February 16, 2024 (the "Grant Date") in connection with the employees' commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 99,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing R

      2/20/24 4:05:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

      -  FDA has granted Priority Review with a target PDUFA date of August 14 - NEWARK, Calif., Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid. The FDA has granted priority review and set a Prescription

      2/12/24 8:45:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

      -- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC -- -- Acquisition Expands Gilead's Long-Standing Commitment to Patients with Liver Diseases -- Gilead Sciences, Inc. (NASDAQ:GILD) and CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay's investigational lead product candidate, seladelpar for the tre

      2/12/24 8:30:00 AM ET
      $CBAY
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • CymaBay Therapeutics to Participate in Upcoming Investment Conferences

      NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY, Raymond James & Associates' 45th Annual Institutional Investors Conference, March 4-6, in Orlando, Florida, and Leerink Partners Global Biopharma Conference, March 11-13, in Miami, Florida. Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceDate: Wednesday, February 7th, 2024Time: 1:00pm Eastern Time, Firesid

      1/31/24 8:00:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to two employees on January 12, 2024 (the "Grant Date") in connection with the employees' commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 52,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing Rule

      1/16/24 4:28:43 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CymaBay Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

      Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing thera

      2/28/24 4:45:25 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023

      NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 1-877-407-0784 from the U.S. and Canada, or 1-201-689-8560 internationally, Conference ID #13740701. To access the live and subsequently archived webcast of the conference call, go t

      10/31/23 4:05:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis

      Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p<0.0001) Normalization of alkaline phosphatase at 12 months was achieved by 25.0% of patients treated with seladelpar vs. 0% on placebo (p<0.0001) In patients having moderate-to-severe itch at baseline, the seladelpar treated group improved their pruritus at 6 months compared to those in the placebo group (p<0.005) Safety and tolerability were comparable between placebo and seladelpar groups and consistent with previous studies CymaBay will hold a conference call to discuss these results today at 8:00 a.m. ET N

      9/7/23 7:00:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023

      NEWARK, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will host an investor call on Thursday, September 7 at 8:00 a.m. ET to share topline results from the Phase 3 pivotal RESPONSE study of seladelpar in patients with primary biliary cholangitis (PBC). To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13741034. To access the live and archived webcast of the conference call, go to the Investors section of t

      9/6/23 4:05:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update

      Top-line data from RESPONSE Phase 3 study in PBC expected by end of September 2023 IDEAL clinical trial actively recruiting Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today corporate updates and financial results for the second quarter ended June 30, 2023. Sujal Shah, President and CEO of CymaBay, stated, "I'm incredibly proud of the progress our teams have made thus far this year as we march towards our key and exc

      8/10/23 4:04:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023

      NEWARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-308-2053 from the U.S. and Canada, or 212-231-2921 internationally, Conference ID # 22027740. To access the live and subsequently archived webcast of the confer

      8/3/23 4:05:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as Chief Financial Officer Results from ENHANCE phase 3 global study of seladelpar in patients with PBC published in Hepatology Completed a public equity offering totaling net proceeds of $92.4 million Entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases, today announced corp

      5/15/23 4:04:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023

      NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 844-825-9789 from the U.S. and Canada, or 412-317-5180 internationally, Conference ID # 10178303. To access the live and subsequently archived webcast of the conference c

      5/10/23 8:00:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update

      NEWARK, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2022. Sujal Shah, President and CEO of CymaBay, stated, "We are off to a fast start in 2023 after making significant progress in 2022 in our development program evaluating seladelpar for patients with primary biliary cholangitis (PBC). Since completing enrollment in RESPONSE, our global phase 3 registration study, in July 2022, we presented data at The Liver Me

      3/16/23 4:04:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

      NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 16, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2022 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID # 13736281. To access the live and subsequently archived webcast

      3/9/23 4:05:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CymaBay Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development

      NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Charles McWherter as President of Research and Development. "We are excited to announce the promotion of Chuck to President of Research and Development, in addition to his continuing role as Chief Scientific Officer. Chuck joined CymaBay in 2007 and has served as Chief Scientific Officer since 2013. In this role he has been instrumental in the development of seladelpar. Chuck's extensive experience in the pharmaceutical industry

      11/1/22 8:01:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors

      NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of Directors. "We are excited to be welcoming Éric to the Board. Éric's extensive experience in the pharmaceutical industry as an executive focused on clinical development, medical affairs, business development and life-cycle strategy and more than 10 years of experience developing drugs in liver disease indications make him a perfect addition to our Board. We look forward to Éric helping guide us thr

      3/17/22 4:25:00 PM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors CymaBay Therapeutics, Inc.

      NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of biopharma veteran Thomas Wiggans and commercial leader Janet Dorling to its Board of Directors. Concurrently with these appointments, CymaBay announced that Paul F. Truex has resigned from the Board of Directors effective as of April 1, 2021 to focus on his new role as Chief Executive Officer of LQT Therapeutics. “We are truly excited to be welcoming Tom and Janet to the Board. Tom’s experience leading biopharma companies, such a

      4/5/21 8:00:00 AM ET
      $CBAY
      Biotechnology: Pharmaceutical Preparations
      Health Care